A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune Thrombocytopenia
Latest Information Update: 01 Aug 2023
At a glance
- Drugs Orelabrutinib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Proof of concept; Therapeutic Use
- Sponsors Innocare Pharma Australia
- 15 Jun 2023 Status changed from recruiting to active, no longer recruiting according to results presented at the 28th Congress of the European Haematology Association
- 15 Jun 2023 Results assessing the efficacy, safety and tolerability oforelabrutinib in patients with persistent or chronic primary ITP presented at the 28th Congress of the European Haematology Association
- 12 Jun 2023 According to an InnoCare Pharma media release, results from this study were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.